SeMaglutide and Albuminuria Reduction Trial in Obese Individuals Without Diabetes

Summary

Study to assess the effects of weekly subcutaneous administration of the GLP1-RA semaglutide 2.4mg on kidney function parameters in obese/overweight individuals at high risk of CKD progression.

Timeline

Start

2022-03-14

Primary completion

2024-05-28

Completion

2024-05-28

Publications

• Heerspink HJL, Soler M, Beernink JM, Jongs N, Cigarran S, Cruzado JM, Puchades MJ, Lopez-Martinez M, Apperloo E, Waanders F, Laverman GD, van der Aart-van der Beek A, van Beek AP, Verhave JC, Ahmed SB, Schmieder RE, Wanner C, Cherney DZI, Gorriz JL. Effects of Semaglutide on Body Composition and GFR: A Prespecified Analysis of the SMART Trial. Clin J Am Soc Nephrol. 2026 Jul 1;21(7):1149-1158. doi: 10.2215/CJN.0000001051. Epub 2026 Apr 30.
• Apperloo EM, Gorriz JL, Soler MJ, Cigarran Guldris S, Cruzado JM, Puchades MJ, Lopez-Martinez M, Waanders F, Laverman GD, van der Aart-van der Beek A, Hoogenberg K, van Beek AP, Verhave J, Ahmed SB, Schmieder RE, Wanner C, Cherney DZI, Jongs N, Heerspink HJL. Semaglutide in patients with overweight or obesity and chronic kidney disease without diabetes: a randomized double-blind placebo-controlled clinical trial. Nat Med. 2025 Jan;31(1):278-285. doi: 10.1038/s41591-024-03327-6. Epub 2024 Oct 25.

Drugs

Indications